Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up

Ophthalmologica

Volumn 226, Issue 3, 2011, Pages 103-109

  Lorenzo, Daniel ^a   Arias, Luis ^a   Alcubierre, Rafel ^a   Pujol, Octavio ^a   Caminal, J M ^a   Rubio, Marcos ^a   Català, Jaume ^a   Garcia Bru, Pere ^a   Arruga, Jorge ^a  

^a Bellvitge University Hospital   (Spain)

Author keywords

Anti vascular endothelial growth factor therapy; Choroidal neovascularization; Pathological myopia; Ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 80053117722     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000328980     Document Type: Article

References (33)

1. Ohno-Matsui K, Oshida T, Futagami S, Yasumuzi K, Shimada N, Kojima A, Tokoro T, Mochizuki M: Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathological myopia. Br J Ophthalmol 2003; 87: 570-573. (Pubitemid 36535327)
2. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial -VIP report No 3. Ophthalmology 2003; 110: 667-673. (Pubitemid 36520061)
3. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA: Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 2005; 89: 1368-1370. (Pubitemid 41638883)
4. Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, Pang CP: Changes in aqueous vascular growth factor and pigment epithelialderived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008; 28: 1308-1313.
5. Cohen SY: Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009; 29: 1062-1066.
6. Yoon JU, Byun YJ, Koh HJ: Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010; 30: 418-424.
7. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, Gabrieli CB: Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab (a randomized controlled trial). Am J Ophthalmol 2010; 149: 458-464.
8. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM: Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006; 26: 960-963. (Pubitemid 44547453)
9. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Oshima Y, Kusaka S, Tano Y: Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 2007; 91: 161-165. (Pubitemid 46202863)
10. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS: Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007; 91: 157-160. (Pubitemid 46202862)
11. Chan WM, Lai TY, Liu DT, Lam DS: Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six month results of a prospective pilot study. Ophthalmology 2007; 114: 2190-2196.
12. Hernández-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solís-Vivanco A, Reyna-Castelán E, Abraham-Marín M, Martínez-Castellanos MA, Aiello LP: Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007; 27: 707-712. (Pubitemid 47051766)
13. Dithmar S, Schaal KB, Höh AE, Schmidt S, Schütt F: Intravitreales Bevacizumab bei choroidaler Neovaskularisation infolge pathologischer Myopie. Ophthalmologe 2009; 106: 527-530.
14. Rensch F, Spandau UH, Schlichtenbrede F, von Baltz S, Libondi T, Jonas JB, Vossmerbaeumer U: Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 2008; 39: 182-185. (Pubitemid 351947661)
15. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB: Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147: 84-93.
16. Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosaa A, Carvalheira F, Abreu JR, Cunha-Vaz JG: Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008; 28: 1117-1123.
17. Arias L, Planas N, Prades S, Caminal JM, Rubio M, Pujol O, Roca G: Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to pathological myopia: 6-month results. Br J Ophthalmol 2008; 92: 1035-1039.
18. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y: Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: oneyear results. Am J Ophthalmol 2009; 147: 94-100.e1.
19. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A: Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247: 311-318.
20. Wu PC, Chen YJ: Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye 2009; 23: 57-60.
21. Chan WM, Lai TY, Liu DT, Lam DS: Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009; 93: 150-154.
22. Monés JM, Amselem L, Serrano A, García M, Hijano M: Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye 2009; 23: 1275-1280.
23. Lai T, Chan W, Liu D, Lam D: Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009; 29: 750-756.
24. Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, Yoshida T, Tokoro T, Mochizuki M: Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009; 148: 396-408.
25. Torrón C, Egea C, Ferrer E, Ruiz O, Honrubia FM: Tratamiento de membranas neovasculares miópicas con ranibizumab. Arch Soc Esp Oftalmol 2009; 84: 507-514.
26. Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T, Takahashi K, Uchihori Y, Gomi F: Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2010; 149: 140-146.
27. Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF, Cachulo ML, Carvalheira F, Murta JN: Intravitreal ranibizumab for myopic choroidal neovascularization (12-month results). Retina 2010; 30: 407-412.
28. Lalloum F, Souied E, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N: Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 2010; 30: 399-406.
29. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, Gabrieli CB: Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab -a randomized controlled trial. Am J Ophthalmol 2010; 149: 458-464.
30. Cornut PL, Poli M, Feldman A, El Chehab H, Swalduz B, Burillon C, Denis P: Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results. J Fr Ophtalmol 2010; 33: 327-333.
31. Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F: Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010; 128: 437-442.
32. Voykov B, Gelisken F, Inhoffen W, Voelker M, Bartz-Schmidt KU, Ziemssen F: Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol 2010; 248: 543-550.
33. Gharbiya M, Allievi F, Conflitti S, Esposito M, Scavella V, Moramarco A, Cruciani F: Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study. Clin Ter 2010; 161:e87-e93.